Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor

Eur J Med Chem. 2019 Feb 1:163:95-115. doi: 10.1016/j.ejmech.2018.11.052. Epub 2018 Nov 24.

Abstract

The rapid emergence of methicillin-resistant Staphylococcus aureus (MRSA) strains has undermined the therapeutic efficacy of existing β-lactam antibiotics (BLAs), prompting an urgent need to discover novel BLAs adjuvants that can potentiate their anti-MRSA activities. In this study, cytotoxicity and antibacterial screening of a focused compound library enabled us to identify a compound, namely 28, which exhibited low cytotoxicity against normal cells and robust in vitro bactericidal synergy with different classes of BLAs against a panel of multidrug-resistant clinical MRSA isolates. A series of biochemical assays and microscopic studies have revealed that compound 28 is likely to interact with the S. aureus FtsZ protein at the T7-loop binding pocket and inhibit polymerization of FtsZ protein without interfering with its GTPase activity, resulting in extensive delocalization of Z-ring and morphological changes characterized by significant enlargement of the bacterial cell. Animal studies demonstrated that compound 28 had a favorable pharmacokinetic profile and exhibited potent synergistic efficacy with cefuroxime antibiotic in a murine systemic infection model of MRSA. Overall, compound 28 represents a promising lead of FtsZ inhibitor for further development of efficacious BLAs adjuvants to treat the staphylococcal infection.

Keywords: 3-Aminobenzamides; FtsZ inhibitor; Methicillin-resistant Staphylococcus aureus; β-Lactam antibiotics.

MeSH terms

  • Animals
  • Bacterial Proteins / antagonists & inhibitors*
  • Binding Sites
  • Cefuroxime / therapeutic use
  • Cytoskeletal Proteins / antagonists & inhibitors*
  • Drug Synergism
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Mice
  • Small Molecule Libraries
  • Staphylococcal Infections / drug therapy
  • Staphylococcus aureus
  • beta-Lactams / therapeutic use*

Substances

  • Bacterial Proteins
  • Cytoskeletal Proteins
  • FtsZ protein, Bacteria
  • Small Molecule Libraries
  • beta-Lactams
  • Cefuroxime